{
  "model": "claude-sonnet-4-20250514",
  "prompt_version": "v2",
  "prompt_name": "Structured with examples",
  "timestamp": "2026-01-19T20:59:15.507970",
  "use_supplements": true,
  "use_variant_context": true,
  "per_article_results": [
    {
      "pmcid": "PMC5508045",
      "has_supplement": true,
      "variants": [
        {
          "variant": "rs9923231",
          "variant_context": "Also known as: VKORC1 1639G>A, VKORC1 rs9923231 reference (C), VKORC1 -1639G>A, VKORC1 -1252G>A",
          "generated": "Variant genotypes of VKORC1 -1639G>A are associated with decreased dose of warfarin in Thai patients as compared to wild-type genotype.",
          "ground_truth": [
            "Genotypes CT + TT are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism or Venous Thrombosis as compared to genotype CC."
          ],
          "best_similarity": 0.37142857142857144,
          "best_match_idx": 0,
          "best_match": "Genotypes CT + TT are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism or Venous Thrombosis as compared to genotype CC.",
          "all_similarities": [
            0.37142857142857144
          ]
        },
        {
          "variant": "rs1057910",
          "variant_context": "Also known as: CYP2C9 1075A>C, CYP2C9*1",
          "generated": "CYP2C9 *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1 in Thai patients.\n\nCYP2C9 *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1 in Thai patients.",
          "ground_truth": [
            "Genotypes AC + CC are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype AA."
          ],
          "best_similarity": 0.2777777777777778,
          "best_match_idx": 0,
          "best_match": "Genotypes AC + CC are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype AA.",
          "all_similarities": [
            0.2777777777777778
          ]
        },
        {
          "variant": "rs2108622",
          "variant_context": "",
          "generated": "CYP4F2 rs2108622 TT genotype is associated with increased dose of warfarin in Thai patients as compared to CC genotype.",
          "ground_truth": [
            "Genotype TT is associated with increased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC."
          ],
          "best_similarity": 0.4666666666666667,
          "best_match_idx": 0,
          "best_match": "Genotype TT is associated with increased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC.",
          "all_similarities": [
            0.4666666666666667
          ]
        },
        {
          "variant": "rs887829",
          "variant_context": "Also known as: UGT1A1 -364C>T, UGT1A1*80",
          "generated": "UGT1A1 rs887829 is not associated with dose of warfarin in Thai patients as compared to wild-type allele carriers.",
          "ground_truth": [
            "Allele C is not associated with dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to allele T."
          ],
          "best_similarity": 0.375,
          "best_match_idx": 0,
          "best_match": "Allele C is not associated with dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to allele T.",
          "all_similarities": [
            0.375
          ]
        }
      ],
      "avg_similarity": 0.372718253968254
    },
    {
      "pmcid": "PMC554812",
      "has_supplement": false,
      "variants": [
        {
          "variant": "HLA-B*58:01",
          "variant_context": "",
          "generated": "HLA-B*58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.",
          "ground_truth": [
            "HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol."
          ],
          "best_similarity": 0.8125,
          "best_match_idx": 0,
          "best_match": "HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.",
          "all_similarities": [
            0.8125
          ]
        },
        {
          "variant": "HLA-DRB1*03:01",
          "variant_context": "",
          "generated": "HLA-B*5801 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.",
          "ground_truth": [
            "HLA-DRB1 *03:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol."
          ],
          "best_similarity": 0.8125,
          "best_match_idx": 0,
          "best_match": "HLA-DRB1 *03:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.",
          "all_similarities": [
            0.8125
          ]
        },
        {
          "variant": "HLA-C*03:02",
          "variant_context": "",
          "generated": "HLA-C*03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol as compared to controls.",
          "ground_truth": [
            "HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol."
          ],
          "best_similarity": 0.65,
          "best_match_idx": 0,
          "best_match": "HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.",
          "all_similarities": [
            0.65
          ]
        },
        {
          "variant": "HLA-A*33:03",
          "variant_context": "",
          "generated": "HLA-A*33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol as compared to controls.",
          "ground_truth": [
            "HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol."
          ],
          "best_similarity": 0.65,
          "best_match_idx": 0,
          "best_match": "HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.",
          "all_similarities": [
            0.65
          ]
        },
        {
          "variant": "rs1594",
          "variant_context": "",
          "generated": "HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.",
          "ground_truth": [
            "Allele A is associated with severe cutaneous adverse reactions when treated with allopurinol as compared to allele G."
          ],
          "best_similarity": 0.47619047619047616,
          "best_match_idx": 0,
          "best_match": "Allele A is associated with severe cutaneous adverse reactions when treated with allopurinol as compared to allele G.",
          "all_similarities": [
            0.47619047619047616
          ]
        }
      ],
      "avg_similarity": 0.6802380952380952
    }
  ],
  "avg_similarity": 0.543562610229277,
  "total_variants": 9,
  "articles_with_supplements": 1
}